Kim Boericke
Chief Executive Officer
Kim Boericke
Chief Executive Officer
Kim Boericke is the Chief Executive Officer of Veristat and is a member of the company’s Executive Leadership Team. She is responsible for developing and implementing the global strategy for the organization which is focused on providing data analytics and insights to accelerate research and development and approvable regulatory submissions. She is known for rigorous standards and an execution-focused approach that supports regulatory clarity and operational consistency across complex development programs. She brings a leadership approach that is grounded in accountability and collaboration with a sharp focus on client and patient outcomes.
A scientifically astute executive with more than 25 years in the clinical research industry, Kim is recognized for expertise in clinical trial design and the implementation of decentralized clinical trials across global regions and therapeutic areas, with an execution-focused style that supports regulatory clarity and operational consistency. She joined Veristat in 2024 as Chief Operating Officer (COO) and previously served as COO at THREAD, with additional executive and senior leadership roles at ICON, IQVIA, ClinTrials, INC Research, Duke Clinical Research Institute and i3 Research. She also served on the board of Mapi Trust as the Chairwoman and an independent director.
Kim graduated from Duke University with a degree in biology and is the author of more than 15 published articles. She is an active mentor within the clinical operations community and a strong advocate for patient centricity, inclusion, and STEM education.
A scientifically astute executive with more than 25 years in the clinical research industry, Kim is recognized for expertise in clinical trial design and the implementation of decentralized clinical trials across global regions and therapeutic areas, with an execution-focused style that supports regulatory clarity and operational consistency. She joined Veristat in 2024 as Chief Operating Officer (COO) and previously served as COO at THREAD, with additional executive and senior leadership roles at ICON, IQVIA, ClinTrials, INC Research, Duke Clinical Research Institute and i3 Research. She also served on the board of Mapi Trust as the Chairwoman and an independent director.
Kim graduated from Duke University with a degree in biology and is the author of more than 15 published articles. She is an active mentor within the clinical operations community and a strong advocate for patient centricity, inclusion, and STEM education.
John P. Balser, PhD
Founder, President, and Chief Statistical Officer
John P. Balser, PhD
Founder, President, and Chief Statistical Officer
John Balser, PhD, co-founder, President & Chief Statistical Officer of Veristat, has developed the company as industry leaders in areas of clinical monitoring, data management, biostatistics and programming, medical writing, and project management. John is actively involved with clinical projects in his role as one of Veristat’s principal statistical consultants. In this role, he assists clients with clinical study design and program development based on his many years of experience in the statistical aspects of clinical research. He is often called upon to aid clients on a variety of statistical issues at meetings with regulatory agencies.
Prior to founding Veristat in 1994, John served as Vice President, Biostatistics, and Data Management at Medical & Technical Research Associates, Inc. He has held positions of increasing responsibility in the biostatistics departments at various pharmaceutical companies including E.R. Squibb, Biogen, and Miles.
John received his MS and PhD in Biometrics from Cornell University, and has been actively engaged in clinical biostatistics for over 30 years. John is an avid runner and has competed in the Boston Marathon.
Prior to founding Veristat in 1994, John served as Vice President, Biostatistics, and Data Management at Medical & Technical Research Associates, Inc. He has held positions of increasing responsibility in the biostatistics departments at various pharmaceutical companies including E.R. Squibb, Biogen, and Miles.
John received his MS and PhD in Biometrics from Cornell University, and has been actively engaged in clinical biostatistics for over 30 years. John is an avid runner and has competed in the Boston Marathon.
Barbara Balser, VMD
Founder, Executive Vice President, and Chief Scientific Officer
Barbara Balser, VMD
Founder, Executive Vice President, and Chief Scientific Officer
Barbara Balser, VMD, co-founder, Executive Vice President and Chief Scientific Officer of Veristat, is primarily responsible for strategic planning and consulting, medical oversight and production of regulatory submission documents. Barbara has more than 30 years of clinical research experience that encompasses both the pharmaceutical and contract research organization industries. Her experience includes oversight and production of Investigational New Drug (IND) applications, regulatory agency briefing documents, preparation for and representation at advisory panel meetings, and consultation across Phase 1 to 4 trials in multiple therapeutic areas with a specific focus in oncology and anti-infectives.
Barbara has participated in the writing, oversight, and submission of multiple marketing applications to US, Canadian, Japanese, and European Union regulatory authorities. Prior to co-founding Veristat, Barbara served as Associate Director of Clinical Research at Medical & Technical Research Associates, Inc. where she was responsible for strategic planning, design, and management of clinical development programs; preparation and submission of regulatory applications; and scientific communications.Barbara began her career in the pharmaceutical industry at Miles, Inc. (currently Bayer Corporation). In her capacity as Assistant Director of Clinical Research at Miles, Barbara assisted with strategic planning for the clinical development of anti-infective compounds from Phases 2 to 4 and with the planning, writing, and compilation of two successful NDAs for anti-infective products. Prior to joining the pharmaceutical and biotech industry, Barbara practiced veterinary medicine at a private veterinary hospital. Barbara holds a BS in Chemical Engineering from the University of Pennsylvania, School of Engineering and Applied Science, and a VMD from the University of Pennsylvania, School of Veterinary Medicine. When Barbara isn’t busy traveling the world for our clients, she enjoys spending time on the beach with a good book.
Barbara has participated in the writing, oversight, and submission of multiple marketing applications to US, Canadian, Japanese, and European Union regulatory authorities. Prior to co-founding Veristat, Barbara served as Associate Director of Clinical Research at Medical & Technical Research Associates, Inc. where she was responsible for strategic planning, design, and management of clinical development programs; preparation and submission of regulatory applications; and scientific communications.Barbara began her career in the pharmaceutical industry at Miles, Inc. (currently Bayer Corporation). In her capacity as Assistant Director of Clinical Research at Miles, Barbara assisted with strategic planning for the clinical development of anti-infective compounds from Phases 2 to 4 and with the planning, writing, and compilation of two successful NDAs for anti-infective products. Prior to joining the pharmaceutical and biotech industry, Barbara practiced veterinary medicine at a private veterinary hospital. Barbara holds a BS in Chemical Engineering from the University of Pennsylvania, School of Engineering and Applied Science, and a VMD from the University of Pennsylvania, School of Veterinary Medicine. When Barbara isn’t busy traveling the world for our clients, she enjoys spending time on the beach with a good book.
Joshua Korth
Chief Financial Officer
Joshua Korth
Chief Financial Officer
Josh joined Veristat in 2024 and serves as Chief Financial Officer. In his role, Josh safeguards Veristat’s financial well-being, leading the company’s global finance function and overseeing all strategic and tactical matters related to financial planning, budget management and forecasting, enhancing profitability and enabling more robust business planning and analysis.
He works closely with Veristat’s executive team to drive the provision of exceptional value to sponsors by leveraging our strengths and solid financial position..
Josh’s career spans more than two decades in financial and leadership positions mentoring teams, driven by a commitment to high standards and quality results. Prior to joining Veristat, Josh served as CFO at Envision Pharma Group. Before this, he held the position of Chief Financial Officer at Two Labs where he played a lead role in optimizing the efficient delivery of commercial services to pharmaceutical manufacturers. His previous CFO roles span a number of large global organizations including Crenlo Cabs, DuBois Chemicals, Schulman IRB (Advarra), and Evenflo. He began his career as an Auditor at KPMG and later worked as a Senior Manager at PwC.
Josh is a certified public accountant (non-active) and attended Indiana University Bloomington where he earned a Bachelor of Science (B.S.) degree in Accounting.
He works closely with Veristat’s executive team to drive the provision of exceptional value to sponsors by leveraging our strengths and solid financial position..
Josh’s career spans more than two decades in financial and leadership positions mentoring teams, driven by a commitment to high standards and quality results. Prior to joining Veristat, Josh served as CFO at Envision Pharma Group. Before this, he held the position of Chief Financial Officer at Two Labs where he played a lead role in optimizing the efficient delivery of commercial services to pharmaceutical manufacturers. His previous CFO roles span a number of large global organizations including Crenlo Cabs, DuBois Chemicals, Schulman IRB (Advarra), and Evenflo. He began his career as an Auditor at KPMG and later worked as a Senior Manager at PwC.
Josh is a certified public accountant (non-active) and attended Indiana University Bloomington where he earned a Bachelor of Science (B.S.) degree in Accounting.
Andrew (AJ) Mills
Executive Vice President, Global Commercial
Andrew (AJ) Mills
Executive Vice President, Global Commercial
Andrew (AJ) Mills serves as Executive Vice President, Global Commercial at Veristat, where he leads all global commercial functions and sits on the Executive Leadership Team. He is responsible for driving growth strategies, strengthening client partnerships, and advancing Veristat’s mission to help bring life-changing therapies to patients worldwide.
With over two decades of leadership experience in pharma services, clinical trials, and health technology, AJ has built a reputation for scaling organizations, leading high-performing teams, and executing commercial transformations. Prior to Veristat, he held executive roles at Lokavant, Saama Technologies, Clario, and ICON, where he spearheaded turnarounds, global expansions, and strategic partnerships that delivered sustained revenue growth and operational excellence. Earlier in his career, AJ founded and led a venture-backed SaaS company and directed commercial operations across clinical platforms, AI/ML analytics, digital endpoints, and temperature-controlled supply chain solutions.
AJ is a frequent industry speaker, published contributor, and mentor to emerging leaders. His expertise spans SaaS, AI/ML analytics, digital endpoints, and clinical development platforms—bringing a rare cross-industry perspective to align innovation with customer and patient needs.
With over two decades of leadership experience in pharma services, clinical trials, and health technology, AJ has built a reputation for scaling organizations, leading high-performing teams, and executing commercial transformations. Prior to Veristat, he held executive roles at Lokavant, Saama Technologies, Clario, and ICON, where he spearheaded turnarounds, global expansions, and strategic partnerships that delivered sustained revenue growth and operational excellence. Earlier in his career, AJ founded and led a venture-backed SaaS company and directed commercial operations across clinical platforms, AI/ML analytics, digital endpoints, and temperature-controlled supply chain solutions.
AJ is a frequent industry speaker, published contributor, and mentor to emerging leaders. His expertise spans SaaS, AI/ML analytics, digital endpoints, and clinical development platforms—bringing a rare cross-industry perspective to align innovation with customer and patient needs.